B-cell Maturation Antigen
B-cell maturation antigen (BCMA) is a protein that serves as a therapeutic target on malignant plasma cells, particularly in multiple myeloma.
B-cell maturation antigen (BCMA) is a protein that serves as a therapeutic target on malignant plasma cells, particularly in multiple myeloma. Its expression on these cells has supported the development of several BCMA-directed approaches, including antibody–drug conjugates such as belantamab mafodotin, bispecific antibodies such as teclistamab, and autologous or allogeneic CAR-T-cell therapies. BCMA is also being investigated in CAR-NK-cell platforms and in treatment strategies for relapsed or refractory AL amyloidosis.
BCMA-directed therapies use different molecular or cellular mechanisms to recognize and eliminate target cells. Teclistamab engages BCMA and CD3 to involve T-lymphocytes, whereas CAR-T and CAR-NK products use engineered immune cells to produce antitumor activity. Ongoing work addresses response, treatment sequencing, persistence, access, and adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Epitope engagement and BCMA mutations may influence the relative activity of different agents, while soluble BCMA and serum M-protein are being evaluated as disease-related pharmacodynamic markers.
- Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. PMID 43035762
Where the papers sit
13 papers from the last 6 months study B-cell Maturation Antigen directly
Study type 2 clinical trials · 3 observational · 5 human data · 2 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
BCMA Therapies in Myeloma
BCMA treatment in multiple myeloma is diversifying across CAR T cells, bispecific antibodies, antibody-drug conjugates and CAR-NK cells. Anito-cel and ciltacabtagene autoleucel extend cellular therapy, while teclistamab and linvoseltamab provide antibody-based options. Epitope engagement and BCMA mutations may determine differential activity, and belantamab mafodotin studies link soluble BCMA and serum M-protein to response. CRS, ICANS and frailty remain central safety concerns.
6 papers · 46.2%
-
CAR-T Cell Therapy
CAR-T therapy is expanding from refractory myeloma into autoimmune disease, with durable drug-free remission reported in primary immune thrombocytopenia and trials emerging in myasthenia gravis. Triple-knockout allogeneic BCMA CAR-T cells aim to improve availability and persistence. CTLA4 and LAG3 variation may help explain differences in progression-free survival after treatment. The field is moving toward off-the-shelf cells and biomarker-guided immune modulation.
4 papers · 30.8%
-
BCMA Therapy in Amyloidosis
BCMA-directed therapy is moving into relapsed or refractory AL amyloidosis, where CAR T cells and bispecific antibodies are producing hematologic responses and organ improvement. Pooled evidence includes minimal residual disease negativity but also Grade 3 cytokine release syndrome. Early high-avidity CAR data support deeper responses, while the French EMMY cohort broadens experience across plasma-cell disease. Prospective studies must clarify durability and safety in amyloidosis.
3 papers · 23.1%
BCMA-directed CAR T-cell therapy extends beyond plasma-cell malignancies to durable treatment of autoimmune disease
Refractory primary immune thrombocytopenia was treated with BCMA-directed CAR T cells, producing rapid, sustained platelet recovery and drug-free complete remission lasting up to 15 months 42498681Jul. The set otherwise presents BCMA as a therapeutic target in malignant or dyscratic plasma-cell disorders, so this finding assigns it a role in refractory autoimmune disease and broadens BCMA-directed cellular therapy beyond cancer treatment.
Papers
The 13 papers from the last 6 months that study B-cell Maturation Antigen directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BCMA Therapies in Myeloma (6)
- Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811422
- Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer · 24 Sept 2026 PMID 42779338
- Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. The New England journal of medicine · 23 Sept 2026 PMID 42777241
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
- Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2 Sept 2026 PMID 42682210
- Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Blood advances · 27 Jul 2026 PMID 42509021
CAR-T Cell Therapy (4)
- Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
- Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
- BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
- A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood · 11 Jun 2026 PMID 42275247
BCMA Therapy in Amyloidosis (3)
- Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. Journal of hematology & oncology · 15 Nov 2026 PMID 43035762
- BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort. European journal of haematology · 29 Sept 2026 PMID 42810732
- Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis. Blood advances · 21 Jul 2026 PMID 42478693
By study type
Clinical trials (2)
- Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. The New England journal of medicine · 23 Sept 2026 PMID 42777241
- A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood · 11 Jun 2026 PMID 42275247
Observational studies and case reports (3)
- Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
- Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer · 24 Sept 2026 PMID 42779338
- Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
Human data, design not indexed (5)
- Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. Journal of hematology & oncology · 15 Nov 2026 PMID 43035762
- Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811422
- Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
- BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
- Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis. Blood advances · 21 Jul 2026 PMID 42478693
Preclinical: animal, cell and lab studies (2)
- Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2 Sept 2026 PMID 42682210
- Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Blood advances · 27 Jul 2026 PMID 42509021
Unclassified: not yet indexed with MeSH (1)
- BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort. European journal of haematology · 29 Sept 2026 PMID 42810732
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-10-14. Drafted by language models from published abstracts; not medical advice.